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Background: Given the paucity of information on dose intensity, the objective of this study is to describe the use
of adjuvant chemotherapy for stage III colon cancer, focusing on relative dose intensity (RDI), overall survival (OS)
and disease-free survival (DFS).
Methods: Retrospective cohort of 367 patients diagnosed with stage III colon cancer in 2003–2008 and treated at
19 VA medical centers. Kaplan-Meier curves summarize 5-year OS and 3-year DFS by chemotherapy regimen and
RDI, and multivariable Cox proportional hazards regression was used to model these associations.
Results: 5-fluorouracil/leucovorin (FU/LV) was the most commonly initiated regimen in 2003 (94.4%) and 2004
(62.7%); in 2005–2008, a majority of patients (60%-74%) was started on an oxaliplatin-based regimen. Median RDI
was 82.3%. Receipt of >70% RDI was associated with better 5-year OS (p < 0.001) and 3-year DFS (P = 0.009) than
was receipt of ≤70% RDI, with 5-year OS rates of 66.3% and 50.5%, respectively and 3-year DFS rates of 66.1% and
52.7%, respectively. In the multivariable analysis of 5-year OS, oxaliplatin + 5-FU/LV (versus 5-FU/LV) (HR = 0.55; 95%
CI = 0.34-0.91), >70% RDI at the first year (HR = 0.58; 95% CI = 0.37-0.89) and married status (HR = 0.66; 95% CI = 0.45-0.97)
were associated with significantly decreased risk of death, while age ≥75 (versus 55–64) (HR = 2.06; 95% CI = 1.25-3.40),
Charlson Comorbidity Index (HR = 1.17; 95% CI = 1.06-1.30), T4 tumor status (versus T1/T2) (HR = 5.88; 95% CI = 2.69-12.9),
N2 node status (HR = 1.68; 95% CI = 1.12-2.50) and bowel obstruction (HR = 2.32, 95% CI = 1.36-3.95) were associated with
significantly increased risk. Similar associations were observed for DFS.
Conclusion: Patients with stage III colon cancer who received >70% RDI had improved 5-year OS. The association
between RDI and survival needs to be examined in studies of adjuvant chemotherapy for colon cancer outside of the VA.
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In patients with stage III colon cancer, oxaliplatin with
intravenous 5-fluorouracil and leucovorin (5-FU/LV) or
oxaliplatin with capecitabine are the preferred adjuvant
chemotherapy regimens [1-4]. However, the survival
benefit of adding oxaliplatin may not be as great among
the elderly [5], and the use of an oxaliplatin-containing
regimen has been shown to decline with age and per-
formance status [5-7].
In addition to the regimen selected, chemotherapy
duration and intensity have been associated with survival
[8-10]. Specifically, two studies suggested that the dur-
ation of fluorouracil adjuvant chemotherapy (i.e., 5–7
months versus 1–4 months and 4–6 cycles versus 1–3
cycles) for stage III colon cancer is associated with im-
proved survival [8,9], and one study of capecitabine ad-
juvant chemotherapy for colorectal cancer (in which
73% of patients had stage III disease) reported that a
relative dose intensity (RDI) of >70% was associated with
improved overall survival [10]. However, it remains un-
clear whether RDI is associated with improved survival
among patients receiving adjuvant chemotherapy for
stage III colon cancer, especially with the use of
oxaliplatin-based regimens.
Having patients complete all intended cycles of
chemotherapy without dose reductions can be difficult
given the toxicities of the medications and concomitant
health problems. Decreased completion of adjuvant
chemotherapy has been reported in the elderly (i.e.,
≥70 years old) and those with comorbidities [8,11], two
characteristics that are common in Veterans. Given the
paucity of information on dose intensity, particularly in
the context of other factors that can impact survival, our
objective is to describe the use of adjuvant chemother-
apy for stage III colon cancer in a Veteran population,
with a focus on associations between RDI and overall
survival (OS) and disease-free survival (DFS). We also
assess factors associated with receiving >70% RDI, OS
and DFS.
Methods
Study setting and population
This is a retrospective cohort study of patients with a
diagnosis of stage III colon cancer between 2003 and
2008 at 19 VA medical centers in the U.S.; patients were
followed through June 2011. Veterans with colon cancer
were identified via a search of local tumor registries or
data warehouses; then, pharmacists at each site reviewed
VA electronic medical records (i.e., Computerized
Patient Record System or CPRS) to ascertain those with
pathology confirmed stage III disease [12]. Pharmacists
also reviewed CPRS to determine which of these identi-
fied patients received adjuvant chemotherapy (defined as
receipt within 120 days of surgical resection) in the VA[13]. The Institutional Review Boards for participating
sites and VA Pharmacy Benefits Management Services
approved the study (see “Competing interests”).
Data sources and data collection
Using CPRS, pharmacists recorded the date of birth,
date of surgical resection, tumor staging (i.e., Tumor,
Node and Metastasis), other prognostic characteristics
(i.e., preoperative carcinoembryonic antigen [CEA];
histologic type and grade; number of lymph nodes eval-
uated; number of positive lymph nodes; margins, and
presence/absence of lymphovascular invasion, perineu-
ral invasion, bowel obstruction and perforation) [14],
Eastern Cooperative Oncology Group (ECOG) per-
formance status prior to initiation of chemotherapy,
time between surgery and start of chemotherapy, adju-
vant chemotherapy regimen administered, adverse drug
events (ADEs) that caused a delay or change in chemo-
therapy, and date of local or distant cancer recurrence.
Patient demographic and comorbidity data were ob-
tained from the VA Medical SAS Datasets (Austin
Information Technology Center in Austin, TX), and
date of death was obtained from the Vital Status file.
Chemotherapy regimens
The standard adjuvant chemotherapy regimens are listed
in Additional file 1: Appendix I. Standard Adjuvant
Chemotherapy Regimens for Colon Cancer. We classi-
fied the regimens as 5-FU/LV, oxaliplatin plus 5-FU/LV,
oxaliplatin plus capecitabine, capecitabine monotherapy
and “other” (e.g., regimens containing bevacizumab, iri-
notecan) based on the active medications.
RDI
RDI is the proportion of the standard regimen (Additional
file 1: Appendix I. Standard Adjuvant Chemotherapy Regi-
mens for Colon Cancer) dose intensity that patients re-
ceived over their course of chemotherapy. RDI was
calculated for each patient according to the method pro-
posed by Hryniuk and Bush [15]. For each drug within
each regimen, the total dosage that the patient received
was divided by the total dosage specified by the corre-
sponding standard regimen; these proportions were aver-
aged across drugs within a given regimen. If patients
switched regimens, the regimen-specific RDIs were
summed.
Primary outcome measures
The primary outcomes were 5-year OS and 3-year DFS.
OS was the time from cessation of chemotherapy to
death from any cause. DFS was the time from cessation
of chemotherapy to either colon cancer recurrence or
death, whichever came first; 3-year DFS has been used
as a surrogate marker for OS in clinical trials of adjuvant
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time origin was the date a patient ceased chemotherapy
because a key independent variable, RDI, was based on
the entire course of adjuvant therapy received.
Statistical analysis
Patient baseline characteristics, including demographics,
comorbidities as defined in the Deyo et al. adaptation of
the Charlson Comorbidity Index minus malignancy [18],
ECOG performance status, tumor staging and other
prognostic factors are described for patients with stage
III colon cancer who received adjuvant chemotherapy in
the VA, overall and by chemotherapy regimen adminis-
tered in the first cycle. For the first cycle of chemother-
apy, we estimated the proportion of patients who
received each regimen by year of pathologically-
confirmed diagnosis. Chi-square or Fisher exact tests
were used to compare categorical variables across initial
regimens, and ANOVA or Kruskal-Wallis tests were
used to compare continuous variables. For subsequent
analyses of RDI and survival considering the entire
course of adjuvant therapy, those patients who switched
to a different regimen after the first cycle were classified
as receiving “mixed/other” chemotherapy.
In preliminary survival analyses we assessed alternative
categorizations of RDI (i.e., <50%, 50%-70%, 71%-84%
and 85%+), then collapsed categories that did not differ
significantly in terms of their association with either OS
or DFS. These analyses confirmed the previously identi-
fied RDI cut point of >70%. We compared the propor-
tions of patients who received ≤70% vs. >70% RDI by
regimen, using Chi-square tests. Multivariable logistic
regression was used to assess factors associated with the
receipt of >70% RDI. We summarized ADE rates overall
and by chemotherapy regimen.
Kaplan-Meier survival curves summarize 5-year OS
and 3-year DFS by chemotherapy regimen and RDI.
Log-rank tests were used to compare subgroups. Multi-
variable Cox proportional hazards regression was used
to evaluate associations between independent variables
of interest and survival outcomes. Independent variables
suggestive of a bivariate association (i.e., P < 0.15) were
included in the initial multivariable models; the final
models included only variables with P < 0.05 for either
OS or DFS. Chemotherapy regimen, RDI, age, sex, ethni-
city/race, Charlson Comorbidity Index, days between
surgery and start of chemotherapy and fixed effects for
site were forced into both models. We tested the
proportional-hazards assumption using time-dependent
covariates. Because this assumption was violated for RDI
>70% in the model for 5-year OS, an interaction term
between RDI >70% and log (year) was added, and annual
time-dependent hazard ratios were estimated using lin-
ear combinations of model parameters. We also testedinteractions between regimens and RDI >70% in both
models. All p-values are two-sided. Data management
was done using SAS software (Cary, NC) version 9.2.
Fisher Exact tests were done using Monte Carlo in Cytel
Studio 7 (Cambridge, MA), and all models were run in
Stata (College Station, TX) version 11.
Results and discussion
Study population
Between 2003 and 2008, 581 patients with pathologically
confirmed stage III colon cancer were treated at the 19
participating VA medical centers. Of these patients, 367
(63.2%) received chemotherapy in the VA within 120 days
of surgical resection. The most common reasons that
patients did not receive chemotherapy in the VA were
patient refused (32%), comorbidities (23%), poor per-
formance status (18%) and chemotherapy prescribed by
non-VA physician (14%). Few baseline characteristics
varied by initial adjuvant chemotherapy regimen
(Table 1). Those who initiated capecitabine monotherapy
tended to be older and relatively more likely to have an
ECOG performance status of 2 to 4.
Adjuvant chemotherapy
The most commonly initiated regimen was 5-FU/LV in
2003 (94.4%) and 2004 (62.7%), while a majority of pa-
tients (60%-74%) started an oxaliplatin-based regimen in
2005–2008 (50%-66% received oxaliplatin plus 5-FU/LV)
(Figure 1). At some point after their first cycle, 57
(15.5%) patients were switched to different adjuvant
chemotherapy regimens, including 26 who started oxali-
platin plus 5-FU/LV. Considering the entire course of
adjuvant therapy, 30.8% received 5-FU/LV; 34.3% re-
ceived oxaliplatin plus 5-FU/LV; 5.4% received oxalipla-
tin plus capecitabine; 12.5% received capecitabine
monotherapy, and 16.9% received “mixed” (i.e., they
switched between regimens) or “other” regimens.
Relative dose intensity
Based on standard adjuvant chemotherapy regimens
(Additional file 1: Appendix I. Standard Adjuvant
Chemotherapy Regimens for Colon Cancer), the median
RDI was 82.3%, and 56.1% of patients completed >70%
RDI (Table 2). Overall, 54.9% of patients completed all
chemotherapy cycles, regardless of dose, and median
time on chemotherapy was 5.4 months. The percentage
of patients completing >70% RDI ranged from 71.4% for
those who received oxaliplatin plus 5-FU/LV to 40%
and 30.4%, respectively, for those who received oxali-
platin plus capecitabine or capecitabine monotherapy.
In the multivariable model, the odds of receiving >70%
RDI were significantly lower in patients below age 55
and above age 64 (versus 55–64 years of age) (age < 55:
OR 0.34; 95% CI 0.14, 0.85; age 65–74: OR 0.46; 95%
Table 1 Baseline characteristics of patients with stage III colon cancer who received adjuvant chemotherapy in VA,
categorized by regimen administered in the first cycle
Characteristic VA Chemotherapy 5-FU/LV Oxaliplatin
plus 5-FU/LV
Oxaliplatin plus
Capecitabine
Capecitabine
Monotherapy
Other p-valuea
N = 367,
N (col%)
N = 126,
N (col%)
N = 152,
N (col%)
N = 30,
N (col%)
N = 48,
N (col%)
N = 11,
N (col%)
Age (mean, SD) 66.4 (9.9) 67.2 (9.3) 63.7 (9.6) 65.6 (9.2) 73.1 (8.5) 66.3 (12.8) <0.001
Age <0.001
<55 39 (10.6) 11 (8.7) 23 (15.1) 3 (10.0) 0 (0.0) 2 (18.2)
55-64 131 (35.7) 41 (32.5) 66 (43.4) 13 (43.3) 8 (16.7) 3 (27.3)
65-74 110 (30.0) 45 (35.7) 38 (25.0) 7 (23.3) 17 (35.4) 3 (27.3)
75+ 87 (23.7) 29 (23.0) 25 (16.4) 7 (23.3) 23 (47.9) 3 (27.3)
Male 360 (98.1) 124 (98.4) 148 (97.4) 30 (100.0) 47 (97.9) 11 (100.0) 0.86
Married 0.92
No 181 (49.3) 62 (49.2) 75 (49.3) 16 (53.3) 24 (50.0) 4 (36.4)
Yes 184 (50.1) 64 (50.8) 75 (49.3) 14 (46.7) 24 (50.0) 7 (63.6)
Missing 2 (0.5) 0 (0.0) 2 (1.3) 0 (0.0) 0 (0.0) 0 (0.0)
Race/Ethnicity <0.001
Hispanic 58 (15.8) 18 (14.3) 32 (21.1) 1 (3.3) 2 (4.2) 5 (45.5)
Black (non-Hispanic) 59 (16.1) 20 (15.9) 25 (16.4) 3 (10.0) 7 (14.6) 4 (36.4)
White (non-Hispanic) 237 (64.6) 83 (65.9) 90 (59.2) 23 (76.7) 39 (81.3) 2 (18.2)
Other/missing 13 (3.5) 5 (4.0) 5 (3.3) 3 (10.0) 0 (0.0) 0 (0.0)
Charlson Comorbidity Indexb
(mean, SD)
1.1 (1.7) 1.3 (1.8) 1.1 (1.9) 0.8 (1.4) 1.2 (1.2) 1.1 (1.0) 0.14
Tumor 0.52
T1 16 (4.4) 4 (3.2) 7 (4.6) 1 (3.3) 3 (6.3) 1 (9.1)
T2 45 (12.3) 15 (11.9) 16 (10.5) 5 (16.7) 9 (18.8) 0 (0.0)
T3 275 (74.9) 94 (74.6) 119 (78.3) 23 (76.7) 31 (64.6) 8 (72.7)
T4 31 (8.4) 13 (10.3) 10 (6.6) 1 (3.3) 5 (10.4) 2 (18.2)
Node 0.51
N1 235 (64.0) 87 (69.0) 96 (63.2) 18 (60.0) 28 (58.3) 6 (54.5)
N2 132 (36.0) 39 (31.0) 56 (36.8) 12 (40.0) 20 (41.7) 5 (45.5)
Histologic type <0.001
Adenocarcinoma 340 (92.6) 118 (93.7) 147 (96.7) 21 (70.0) 45 (93.8) 9 (81.8)
Unknown 24 (6.5) 8 (6.3) 3 (2.0) 9 (30.0) 3 (6.3) 1 (9.1)
Other 3 (0.8) 0 (0.0) 2 (1.3) 0 (0.0) 0 (0.0) 1 (9.1)
Histologic grade 0.68
Well differentiated 35 (9.5) 15 (11.9) 10 (6.6) 2 (6.7) 7 (14.6) 1 (9.1)
Moderately differentiated 247 (67.3) 81 (64.3) 107 (70.4) 23 (76.7) 29 (60.4) 7 (63.6)
Poorly differentiated 68 (18.5) 25 (19.8) 27 (17.8) 4 (13.3) 10 (20.8) 2 (18.2)
Undifferentiated 4 (1.1) 0 (0.0) 4 (2.6) 0 (0.0) 0 (0.0) 0 (0.0)
Unknown 13 (3.5) 5 (4.0) 4 (2.6) 1 (3.3) 2 (4.2) 1 (9.1)
Number of lymph nodes evaluated 0.03
<12 132 (36.0) 53 (42.1) 48 (31.6) 8 (26.7) 19 (39.6) 4 (36.4)
12+ 229 (62.4) 68 (54.0) 104 (68.4) 22 (73.3) 29 (60.4) 6 (54.5)
Missing 6 (1.6) 5 (4.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (9.1)
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Table 1 Baseline characteristics of patients with stage III colon cancer who received adjuvant chemotherapy in VA,
categorized by regimen administered in the first cycle (Continued)
Number of lymph nodes evaluated
(mean, SD)
15.6 (8.9) 14.3 (8.5) 16.6 (9.2) 16.5 (10.0) 15.1 (8.8) 15.3 (7.0) 0.11
Number of positive lymph nodes
(mean, SD) (N = 366)
3.8 (4.0) 3.4 (3.8) 3.9 (3.9) 4.8 (5.2) 3.6 (3.5) 6.0 (5.7) 0.10
Preoperative CEA 0.68
<5 ng/ml 178 (48.5) 60 (47.6) 78 (51.3) 14 (46.7) 20 (41.7) 6 (54.5)
≥5 ng/ml 84 (22.9) 32 (25.4) 36 (23.7) 6 (20.0) 8 (16.7) 2 (18.2)
Missing 105 (28.6) 34 (27.0) 38 (25.0) 10 (33.3) 20 (41.7) 3 (27.3)
Preoperative CEA (mean, SD) (N = 262) 8.0 (15.2) 9.4 (18.8) 7.8 (14.2) 4.8 (6.3) 7.1 (11.5) 5.2 (6.3) 0.48
Lymphovascular invasion 0.003
Yes 134 (36.5) 41 (32.5) 62 (40.8) 10 (33.3) 17 (35.4) 4 (36.4)
No 103 (28.1) 26 (20.6) 41 (27.0) 17 (56.7) 17 (35.4) 2 (18.2)
Unknown 130 (35.4) 59 (46.8) 49 (32.2) 3 (10.0) 14 (29.2) 5 (45.5)
Perineural invasion 0.01
Yes 38 (10.4) 8 (6.3) 17 (11.2) 4 (13.3) 6 (12.5) 3 (27.3)
No 102 (27.8) 28 (22.2) 45 (29.6) 15 (50.0) 13 (27.1) 1 (9.1)
Unknown 227 (61.9) 90 (71.4) 90 (59.2) 11 (36.7) 29 (60.4) 7 (63.6)
Bowel obstruction 0.89
Yes 75 (20.4) 27 (21.4) 26 (17.1) 7 (23.3) 13 (27.1) 2 (18.2)
No 168 (45.8) 56 (44.4) 73 (48.0) 14 (46.7) 21 (43.8) 4 (36.4)
Unknown 124 (33.8) 43 (34.1) 53 (34.9) 9 (30.0) 14 (29.2) 5 (45.5)
Perforation 0.19
Yes 21 (5.7) 13 (10.3) 5 (3.3) 2 (6.7) 0 (0.0) 1 (9.1)
No 229 (62.4) 74 (58.7) 94 (61.8) 20 (66.7) 34 (70.8) 7 (63.6)
Unknown 117 (31.9) 39 (31.0) 53 (34.9) 8 (26.7) 14 (29.2) 3 (27.3)
Margins 0.003
All margins histologically negative 307 (83.7) 100 (79.4) 138 (90.8) 20 (66.7) 39 (81.3) 10 (90.9)
1 or more margins included 25 (6.8) 9 (7.1) 10 (6.6) 2 (6.7) 4 (8.3) 0 (0.0)
Unknown 35 (9.5) 17 (13.5) 4 (2.6) 8 (26.7) 5 (10.4) 1 (9.1)
ECOG performance statusc 0.006
0 96 (26.2) 26 (20.6) 52 (34.2) 7 (23.3) 6 (12.5) 5 (45.5)
1 44 (12.0) 19 (15.1) 14 (9.2) 2 (6.7) 8 (16.7) 1 (9.1)
2 -4 20 (5.4) 8 (6.3) 3 (2.0) 1 (3.3) 7 (14.6) 1 (9.1)
Missing or unknown 207 (56.4) 73 (57.9) 83 (54.6) 20 (66.7) 27 (56.3) 4 (36.4)
Days between surgery and start of
chemotherapy
0.053
≤30 12 (3.3) 5 (4.0) 4 (2.6) 0 (0.0) 3 (6.3) 0 (0.0)
31-60 232 (63.2) 95 (75.4) 85 (55.9) 19 (63.3) 27 (56.3) 6 (54.5)
61-90 90 (24.5) 21 (16.7) 45 (29.6) 7 (23.3) 13 (27.1) 4 (36.4)
91-120 33 (9.0) 5 (4.0) 18 (11.8) 4 (13.3) 5 (10.4) 1 (9.1)
5-FU/LV = 5-fluouracil/leucovorin; CEA = carcinoembryonic antigen; ECOG = Eastern Cooperative Oncology Group.
aChi-square tests or Fisher exact tests for categorical variables and ANOVA for continuous variable of age.
bMalignancy was removed from the Charlson Comorbidity Index because all patients have colon cancer.
cECOG performance status prior to initiation of chemotherapy.
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Figure 1 Adjuvant chemotherapy regimen received in the first cycle by year of pathology confirmed diagnosis. “Other” includes 3
patients who received an oxaliplatin-based regimen plus bevacizumab; 6 patients who received an irinotecan-based regimen, and 2 patients who
received a regimen not listed.
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among those who received capecitabine monotherapy
(OR 0.27; 95% CI 0.12, 0.61 relative to 5-FU/LV). No
other factors considered were significantly associated
with completing >70% RDI (Additional file 1: Appendix
II. Multivariable Model of Factors Associated with
Receiving >70% RDI).
Adverse drug events
Among the 367 patients, 259 (70.6%) reported a total
of 660 ADEs that caused a delay or change in chemo-
therapy. The most common ADEs included neutropenia
(N = 154, 23.3% of total ADEs), diarrhea/gastrointestinal
toxicity (N = 134, 21.3%) and thrombocytopenia (N = 114,
17.3%) (Additional file 1: Appendix III. Number of Ad-
verse Drug Events and Rate per 10 Cycles by Regimen). At
the episode level, overall ADE rates were similar across
regimens (2.2-2.5 per 10 cycles of chemotherapy), al-
though some individual ADE rates (e.g., neutropenia,
hand-foot syndrome) differed across regimens. ADEs were
reported by relatively more patients who receivedTable 2 Relative Dose Intensity (RDI), patients completing all
regimen
Outcomes Total 5-FU/LV
N = 367 N = 113
Patients completing ≤70% of RDI, n (col%) 122 (33.2) 35 (31.0)
Patients completing >70% of RDI, n (col%) 206 (56.1) 70 (61.9)
Missing or unknown,b n (col%) 39 (10.6) 8 (7.1)
RDI (%), median (IQR) 82.3 (49.7, 97.5) 96.7 (52.0, 1
Patients completing all cycles (N = 348),
n (row%)
191 (54.9) 79 (73.8)
Months of chemotherapy, median (IQR) 5.4 (4.3, 6.2) 5.2 (4.5, 6.6)
IQR = interquartile range (25th percentile, 75th percentile).
a“Mixed/other” includes patients who switched regimens and those who received a
b39 (10.6%) categorized as missing because the regimen was not standard, or regim
Note: P < 0.0001 for the difference across regimens in categorical variables of RDI and pa
tests, respectively; P < 0.001 for differences across regimens in continuous RDI, and P = 0.oxaliplatin plus 5-FU/LV (78.7%) and relatively fewer pa-
tients who received 5-FU/LV (49.4%); corresponding fig-
ures ranged from 65%-69% for the other regimens (data
not tabled).
Overall survival and disease-free survival
Of the 367 patients who received adjuvant chemother-
apy in the VA during the study period, 132 (36.0%)
died by year 5, and 146 (39.8%) died or had a recur-
rence of their colon cancer by year 3. Oxaliplatin plus
5-FU/LV was associated with better OS than was 5-
FU/LV (p = 0.04); the 5-year OS rates were 69.5% and
54.0%, respectively (Figure 2A). Similar estimates were
obtained for 3-year DFS (69.6% and 56.6%, respect-
ively), and between-regimen differences in DFS were of
borderline statistical significance (P = 0.06, Figure 2B).
Receipt of >70% RDI was associated with better 5-year
OS (p < 0.001) and 3-year DFS (P = 0.009) than was re-
ceipt of ≤70% RDI, with 5-year OS of 66.3% and 50.5%,
respectively and 3-year DFS rates of 66.1% and 52.7%,
respectively (Figures 3A and B). The Kaplan-Meier plotcycles of chemotherapy and months of chemotherapy by
Oxaliplatin
plus 5-FU/LV
Oxaliplatin plus
Capecitabine
Capecitabine
Monotherapy
Mixed/Othera
N = 126 N = 20 N = 46 N = 62
25 (19.8) 11 (55.0) 30 (65.2) 21 (33.9)
90 (71.4) 8 (40.0) 14 (30.4) 24 (38.7)
11 (8.7) 1 (5.0) 2 (4.3) 17 (27.4)
00) 86.1 (70.9, 96.3) 62.2 (46.9, 81.4) 51.2 (29.2, 72.1) 68.8 (42.8, 90.2)
71 (58.2) 6 (30.0) 18 (40.0) 17 (31.5)
5.6 (4.9, 6.1) 4.5 (3.1, 5.6) 4.9 (2.1, 5.6) 5.5 (3.6, 6.4)
chemotherapy regimen not listed.
en data were missing. Therefore, RDI could not be calculated.
tients completing all cycles of chemotherapy using Fisher exact tests and Chi-square
007 for differences in length of chemotherapy using Kruskal-Wallis tests.
Figure 2 Kaplan-Meier estimates of survival by chemotherapy regimen received. A. Kaplan-Meier estimates of overall survival by
chemotherapy regimen received. B. Kaplan-Meier estimates of disease-free survival by chemotherapy regimen received.
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apparently protective effect of >70% RDI.
In the multivariable analysis of factors associated with
5-year OS (Table 3), oxaliplatin plus 5-FU/LV (versus 5-
FU/LV) (HR 0.55; 95% CI 0.34, 0.91), >70% RDI at the
first year (HR 0.58; 95% CI 0.37, 0.89) and being married
(HR 0.66; 95% CI 0.45, 0.97) were associated with de-
creased mortality, while age ≥75 (versus 55–64 years of
age) (HR 2.06; 95% CI 1.25, 3.40), Charlson Comorbidity
Index (HR 1.17; 95% CI 1.06, 1.30), T4 tumor status
(versus T1/T2) (HR 5.88; 95% CI 2.69, 12.9), N2 node
status (HR 1.68; 95% CI 1.12, 2.50) and bowel obstruc-
tion (HR 2.32, 95% CI 1.36, 3.95) were associated with
increased mortality. In the multivariable model of 3-year
DFS, similar associations were observed between most
of these factors and cancer recurrence/death prior torecurrence; no significant differences were identified
by regimen. Interactions between regimen and receipt
of >70% RDI were not statistically significant in either
model (P > 0.20 for each).
Discussion
Our study fills an important void in the literature re-
garding an association between RDI and 5-year OS
among patients receiving adjuvant chemotherapy for
stage III colon cancer. In addition, our study compre-
hensively evaluated other factors that have been associated
with survival, including demographics, comorbidities,
tumor pathology, clinical findings, preoperative CEA and
chemotherapy regimen due to the richness of the VA elec-
tronic medical record. [2,3,14,19] Veterans predominantly
received adjuvant chemotherapy regimens that were
Figure 3 Kaplan-Meier estimates of survival by relative dose intensity. A. Kaplan-Meier estimates of overall survival by relative dose intensity.
B. Kaplan-Meier estimates of disease-free survival by relative dose intensity.
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the initial results of the MOSAIC trial were published,
oxaliplatin + 5-FU/LV was prescribed for the majority of
patients [2]. That very few patients received bevacizumab
mirrors evidence-based practice [20,21]. VA adjuvant
chemotherapy use is consistent with that reported outside
of the VA [7]. Our “real-world” observation that older and
“sicker” (i.e., higher ECOG performance status) patients
were more likely to receive capecitabine monotherapy,
and less likely to receive oxaliplatin + 5FU/LV, is consistent
with other studies that have reported decreased use of
oxaliplatin-based regimens among the elderly and those
with poor performance status [5-7]. Physicians may have
been concerned about the ability of these patients to toler-
ate the more serious toxicities of oxaliplatin.Increased age and comorbidity also can contribute to
decreased completion of chemotherapy [8,11,19], and a
shorter duration of chemotherapy has been associated
with poorer survival in stage III colon cancer. Other
studies have reported that patients who received 5–7
months of 5-FU/LV had lower overall mortality than
those who received 1–4 months (HR 0.59; 95% CI 0.49,
0.71) [8], and that patients who failed to complete 4–6
cycles of 5-FU/LV had higher cancer-specific mortality
(HR 2.24; 95% CI 1.66, 3.03) [9]. However, these studies
did not consider the chemotherapy dose. One study
published in abstract form examined the association be-
tween capecitabine dose intensity and survival in colo-
rectal cancer patients and reported that patients
receiving >70% RDI had improved relapse-free survival
Table 3 Multivariable cox models for overall and disease-free survivala
Overall survival (5 years)b Disease free survivalc (3 years)
HR (95% CI) P values HR (95% CI) P values
Chemotherapy regimens
5-FU/ LV Reference Reference
Oxaliplatin plus 5-FU/LV 0.55 (0.34,0.91) 0.02 0.65 (0.41,1.05) 0.08
Oxaliplatin plus Capecitabine 1.15 (0.42,3.16) 0.79 1.07 (0.42,2.70) 0.89
Capecitabine Monotherapy 0.80 (0.43,1.50) 0.50 0.91 (0.50,1.64) 0.75
Mixed/Other 0.89 (0.50,1.59) 0.70 1.20 (0.70,2.05) 0.51
Relative dose intensity
≤70% Reference Reference
>70% NAd 0.75 (0.50,1.11) 0.15
At year 1 0.58 (0.37,0.89) 0.01
At year 2 0.74 (0.47,1.18) 0.21
At year 3 0.86 (0.52,1.44) 0.57
At year 4 0.96 (0.54,1.68) 0.88
At year 5 1.04 (0.56,1.91) 0.90
Unknown or Missing 0.95 (0.51,1.78) 0.88 0.97 (0.53,1.77) 0.91
Age (years)
<55 0.68 (0.30, 1.52) 0.34 1.00 (0.50, 1.97) 0.99
55-64 Reference Reference
65-74 0.99 (0.61,1.62) 0.96 1.14 (0.72,1.82) 0.57
75+ 2.06 (1.25,3.40) 0.005 1.98 1.21,3.23) 0.006
Male 1.70 (0.39,7.52) 0.48 1.67 (0.39,7.27) 0.49
Race/Ethnicity
White (non-Hispanic) Reference Reference
Hispanic 0.56 (0.17,1.80) 0.33 0.27 (0.08,0.93) 0.04
Black (non-Hispanic) 0.75 (0.37,1.50) 0.41 0.76 (0.40,1.44) 0.40
Other/Missing 1.42 (0.58,3.48) 0.44 1.35 (0.59,3.11) 0.48
Charlson Comorbidity Index (per unit) 1.17 (1.06,1.30) 0.002 1.15 (1.04,1.27) 0.007
Married 0.66 (0.45,0.97) 0.03 0.86 (0.59,1.24) 0.42
Tumor
T1/T2e Reference Reference
T3 1.62 (0.83,3.14) 0.15 1.63 (0.88,3.02) 0.12
T4 5.88 (2.69,12.9) <0.001 5.84 (2.82,12.1) <0.001
Node
N1 Reference Reference
N2 1.68 (1.12,2.50) 0.01 1.89 (1.30,2.77) 0.001
Lymphovascular invasion
No Reference Reference
Yes 1.69 (0.90,3.17) 0.10 1.95 (1.10,3.45) 0.02
Unknown or Missing 1.09 (0.57,2.07) 0.79 1.20 (0.66,2.16) 0.55
Bowel obstruction
No Reference Reference
Yes 2.32 (1.36,3.95) 0.002 2.12 (1.28,3.51) 0.003
Unknown or Missing 1.05 (0.57,1.95) 0.88 1.19 (0.67,2.10) 0.56
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Table 3 Multivariable cox models for overall and disease-free survivala (Continued)
Days between surgery and start of chemotherapy
≤30 Reference Reference
31-60 1.44 (0.40,5.22) 0.58 1.14 (0.37,3.49) 0.82
61-90 1.65 (0.43,6.25) 0.47 1.35 (0.42,4.33) 0.61
91-120 1.84 (0.46,7.41) 0.39 1.56 (0.46,5.32) 0.47
aVariable selection: Predictor variables that were suggestive of a bivariate association (i.e., P < 0.15) were included in the initial multivariable model, and then the
final models included only variables with P < 0.05 in either model. Chemotherapy regimens, RDI, age, sex, ethnicity/race, Charlson Comorbidity Index, days
between surgery and start of chemotherapy, and fixed effects for site were forced into both models.
bA hazard ratio (HR) >1 indicates the covariate is associated with an increased risk of death from any cause, and therefore, decreased overall survival.
cA HR > 1 indicates the covariate is associated with an increased risk of colon cancer recurrence or death, and therefore, decreased disease-free survival.
dThe proportional-hazards assumption does not hold for RDI in the overall survival model. The log hazard of RDI > 70% at time 0 is −0.52 (95% CI −0.94, −0.09),
and the log hazard for the interaction between time (year) and RDI > 70% is 0.37 (95% CI 0.07, 0.66), P = 0.01, which indicates that the protective effect of RDI > 70%
attenuates over time.
eT1 andT2 were collapsed because of small sample size, and both are typically together in the anatomic staging/prognostic groups of stage III colon cancer.
Aspinall et al. BMC Cancer  (2015) 15:62 Page 10 of 13(HR 0.37; 95% CI 0.17-0.82) and OS (HR 0.35; 95% CI
0.14-0.88) [10]. An RDI of >70% also has been associated
with improved 5-year survival in non-Hodgkin’s lymph-
oma [22,23]. Similarly, we found that >70% RDI was as-
sociated with both 3-year DFS and 5-year OS in
unadjusted Cox proportional hazards models and 5-year
OS in the multivariable analysis. The benefit was seen
only in the first year after the completion of chemother-
apy. This attenuation is likely related to the influence of
comorbidities on survival among a more elderly popula-
tion receiving chemotherapy in the adjuvant setting. Our
median RDIs for 5-FU/LV and oxaliplatin plus 5-FU/LV
are similar to those reported in the randomized con-
trolled trial of 5-FU/LV alone or oxaliplatin plus 5-FU/
LV as adjuvant treatment for colon cancer (MOSAIC
trial) (i.e., 97.7% for 5-FU alone; 80.5% for oxaliplatin
and 84.4% for 5-FU in the group given oxaliplatin plus
5-FU/LV [2].
Although previously published studies have reported
an association between age, marital status and comorbidi-
ties and completion of chemotherapy [8,11], we did not
observe similar associations with receipt of RDI >70%.
Perhaps, physicians considered some of these factors when
discussing chemotherapy options with patients. There was
a 73% decrease in the odds of receiving >70% RDI in those
who took capecitabine monotherapy, and the point esti-
mate was comparable in those who received oxaliplatin
plus capecitabine. Our dosing data were obtained primar-
ily from pharmacy dispensing records and do not account
for doses that were not taken unless that was docu-
mented in the oncology notes; we may be overestimat-
ing the actual proportion of patients completing >70%
RDI. Noncompliance with capecitabine has been re-
ported and illustrates the need to ask patients about ad-
herence [24,25].
Our 3-year DFS rate for 5-FU/LV is slightly lower than
that reported in the MOSAIC trial for patients with
stage III disease, but similar for oxaliplatin plus 5-FU/LV
(65.3% for 5-FU/LV and 72.2% for oxaliplatin plus 5-FU/LV)[2]. Likewise, our 5-year OS rate for 5-FU/LV is slightly
lower than the 6-year OS rate in MOSAIC, but similar
for oxaliplatin plus 5-FU/LV (68.7% for 5-FU/LV and
72.9% for oxaliplatin plus 5-FU/LV) [3]. This is likely
related to patient population differences (e.g., age and
comorbidities), especially those who received 5-FU/LV
alone, and to some extent, our choice of time origin.
Similar factors were associated with 5-year OS and 3-
year DFS in our multivariable models. Although some
variables did not reach statistical significance in both
models, the point estimates were comparable. Consistent
with MOSAIC trial results, improved OS was seen in pa-
tients who received oxaliplatin + 5-FU/LV as compared
with 5-FU/LV alone [3]. This is important because of the
factors associated with OS, only regimen and RDI are
potentially modifiable. Even after adjusting for these two
variables and other prognostic factors, age ≥ 75 years
old, having more comorbidities and not being married
were associated with decreased OS. Although survival
benefit with adjuvant chemotherapy in elderly patients
with stage III colon cancer has been reported [5], such
patients may have more coexisting conditions that limit
OS compared with younger patients [9,26]. The number
of comorbidities has been associated with decreased sur-
vival in other studies of colon cancer [27,28]. Finally, be-
ing married may contribute to improved overall survival
because of better emotional support. In a recent analysis
of marital status and cancer-related mortality, which in-
cluded colorectal cancer, unmarried patients had a
higher risk of death from their cancer [29].
Although our study was comprehensive in its assessment
of factors associated with survival, there are potential limi-
tations. First, we did not collect data on subsequent
chemotherapy among those who had cancer recurrences.
This could have positively or negatively affected 5-year OS
depending upon the proportion who were treated for the
recurrence. Second, while receipt of >70% RDI was not sig-
nificantly associated with 3-year DFS in the multivariable
model, the point estimate did suggest a potential protective
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association. The statistical non-significance of the adjusted
association could be due to a small sample size. Third, pa-
tients who received capecitabine monotherapy were older
on average and had worse performance status than those
who received other adjuvant regimens. This may have con-
tributed to relatively fewer of them receiving >70% RDI;
however, DFS and OS with capecitabine monotherapy were
not significantly different from 5-FU/LV in our study.
Fourth, our population was predominantly male, so our re-
sults may not apply to females. However, sex was not inde-
pendently associated with survival in a study of adjuvant
chemotherapy in the community [26]. Finally, our study
was observational, and outcomes may have been influ-
enced by unmeasured clinical characteristics.
Conclusions
In conclusion, we found that patients with stage III
colon cancer who received >70% RDI had improved 5-
year OS after adjusting for other prognostic factors. We
believe our study offers powerful “real world” data that
demonstrate not only the effectiveness of adjuvant
chemotherapy for stage III colon cancer, but also under-
score the importance of administering recommended
doses. The association between RDI and survival needs
to be examined in studies of adjuvant chemotherapy for
colon cancer outside of the VA.
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